Immunome, Inc. (NASDAQ:IMNM) Receives $33.45 Consensus Target Price from Analysts

Posted by Francis Steltz on May 15th, 2026

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $33.4545.

A number of research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Stephens dropped their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Craig Hallum boosted their price objective on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Immunome in a research note on Wednesday.

Get Our Latest Analysis on IMNM

Immunome Trading Down 0.8%

Shares of IMNM opened at $22.02 on Friday. Immunome has a 1 year low of $7.62 and a 1 year high of $27.65. The stock has a 50 day simple moving average of $21.99 and a 200-day simple moving average of $21.19. The stock has a market cap of $2.49 billion, a PE ratio of -9.25 and a beta of 2.11.

Immunome (NASDAQ:IMNM – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, sell-side analysts forecast that Immunome will post -2.5 EPS for the current fiscal year.

Insider Activity

In other news, Director Philip Wagenheim sold 36,800 shares of Immunome stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00. Following the transaction, the director owned 369,347 shares in the company, valued at $7,560,533.09. The trade was a 9.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the transaction, the insider owned 22,000 shares of the company’s stock, valued at $476,080. This represents a 30.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 139,438 shares of company stock valued at $2,964,664 in the last 90 days. 7.21% of the stock is owned by company insiders.

Institutional Trading of Immunome

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in shares of Immunome during the first quarter worth $1,507,000. Sei Investments Co. boosted its stake in Immunome by 90.4% in the 1st quarter. Sei Investments Co. now owns 52,770 shares of the company’s stock worth $1,154,000 after purchasing an additional 25,051 shares during the period. Walleye Capital LLC bought a new position in Immunome during the 1st quarter worth about $2,432,000. KBC Group NV acquired a new stake in shares of Immunome in the 1st quarter valued at about $60,000. Finally, Assetmark Inc. raised its stake in shares of Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.